Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00399750 · ClinicalTrials.gov registry record · Phase 2
TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 373
- Enrollment target
NCT00399750 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 373 participants.
The verdict
NCT00399750, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 373 participants
- Enrollment target
Study Summary
A randomized, controlled, open-label multicenter trial to assess the safety and efficacy of 3 oxaliplatin-fluoropyrimidine containing regimens (mFOLFOX6; bFOL; XELOX) + Bevacizumab (TREE1 and TREE2) as first line therapy of advanced metastatic colorectal cancer.
Interventions
- DRUG bevacizumab
- DRUG oxaliplatin
- DRUG fluoropyrimidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 373 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00399750
The ClinicalTrials.gov registry entry for NCT00399750 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 373 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which bevacizumab is the first listed.
NCT00399750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00399750 about?
NCT00399750 is a clinical study titled "TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer". A randomized, controlled, open-label multicenter trial to assess the safety and efficacy of 3 oxaliplatin-fluoropyrimidine containing regimens (mFOLFOX6; bFOL; XELOX) + Bevacizumab (TREE1 and TREE2) as first line therapy of advanced metastatic colorectal cancer.
What is the current status of trial NCT00399750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 373 participants. The study started on 2002-11. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00399750?
The interventions under investigation include: bevacizumab (DRUG), oxaliplatin (DRUG), fluoropyrimidine (DRUG).
Who is sponsoring clinical trial NCT00399750?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.